Ibogaine for opioids, fentanyl, methadone and Suboxone

Opioid withdrawal is the reason most Americans go to an ibogaine program, and opioids are also where every death in the 2026 clinic cohort happened. Two things decide how an opioid patient's week goes: what they arrive on, and how long the program makes them wait.

Checked October 20, 2026. Sources at the end.

Why long-acting opioids have to go first

Ibogaine potentiates whatever opioid is still in the body. The GITA guidelines put it plainly: patients withdrawing from long-acting opioids "should switch to shorter acting opioids, such as morphine sulfate, prior to treatment", and anyone who uses opioids during treatment "is at immediate risk for overdose". Methadone adds a second problem: it blocks the same cardiac potassium channel (hERG) that ibogaine blocks, prolongs the QT interval on its own and in rare cases causes torsades by itself. The 2017 Netherlands death was a woman on methadone. The FDA's October 2026 trial proposal says participants should discontinue methadone and buprenorphine before dosing and asks sponsors how to handle the loss of opioid tolerance that follows.

Buprenorphine is the other common arrival drug. Its receptor affinity means it can blunt ibogaine's effect or trigger precipitated withdrawal, and its long half-life means the window is counted in weeks.

What each program says the wait is

Arriving on	Stated window	Who states it	Source
Buprenorphine (Suboxone, Subutex)	Counting a 24-hour half-life, 4 mg a day "would be cleared for treatment by day 6"; on a conservative 72-hour half-life, "switch for at least 18 days". Target residual dose no more than 0.125 mg.	GITA guidelines, 2016	Source
Methadone	Counting a 24-hour half-life, 100 mg a day is "cleared for treatment on day 7"; on a conservative 48-hour half-life, "switch for at least 14 days". Target residual dose no more than 2 mg. Dosing 24 hours after the last methadone with a week of boosters "is not recommended".	GITA guidelines, 2016	Source
Methadone or buprenorphine	Eight inpatient days on oral morphine every four hours; last morphine four hours before ibogaine.	Knuijver et al., Addiction 2022 (hospital study)	Source
Methadone	4 to 6 weeks off, with short-acting substitution.	New Roots Ibogaine (clinic blog)	Source
Methadone or Subutex	Switch to a short-acting opioid at least 4 weeks before, or join the 12 to 14 day detox programme.	Tabula Rasa Retreat	Source
Suboxone or methadone	Up to a month of pre-care before ibogaine; a 30-day minimum stay is recommended.	Iboga Treatment Center, Ensenada	Source
Suboxone or methadone	"Careful transition to short-acting opioids before ibogaine treatment"; no timeframe published. Fentanyl users: minimum 21-day stay since January 2026.	Ambio	Source
Suboxone and methadone	Sold as a separate "Suboxone and Methadone Transition" program, 14-day base, $15,500.	MindScape Retreat	Source
Methadone	"Need to switch to short-acting opioids before treatment can begin"; stays of 12 days to two months.	Experience Ibogaine	Source
Suboxone, methadone, SSRIs	Tapers scheduled with the patient's own prescriber; "no dosing until long-acting opioids clear".	Ibogaine Treatment MX	Source
Methadone, Suboxone	12 to 14 days or more for the transition.	New Path Ibogaine	Source
Sublocade, Brixadi	No program page stating a window was found. Sublocade's half-life is 43 to 60 days and buprenorphine can be detectable for months after the last injection.	Pharmacology (patient-education page citing the label)	Source

Two things stand out. First, the "30 to 90 days" sometimes quoted for methadone does not appear on any program page we read; the longest program-stated window is "21 to 30 days" on a medical-tourism page. Second, the one program on this site reported as saying detox beforehand is unnecessary (Ibogaine Clinic by David Dardashti, per Lucid News) is at odds with the guidelines and with every hospital study.

Fentanyl

No program we found refuses fentanyl patients outright. The pattern is longer stays. After a patient in its detox program died in January 2026, Ambio introduced a minimum 21-day stay for anyone who had been using fentanyl, "enhanced screening protocols" and longer detox programs, and acknowledged this makes treatment less affordable for some. The Global Ibogaine Therapy Alliance warned at the same time that nitazenes and xylazine, which are now common adulterants in street fentanyl, evade standard drug screens. In the 2026 clinic cohort, the six deaths involved fentanyl in three cases, heroin in one, methadone plus oxycodone in one and unknown opioids in one. The 2016 guidelines predate the fentanyl era and note only that fentanyl does not show on a standard opiate urine test.

Timing the dose

The guidelines stabilise the patient on oral morphine at the lowest dose that controls withdrawal, then dose ibogaine when early withdrawal is objectively present (an OOWS score of 3 to 7) and delay if it is severe (10 or more). The Dutch study gave the last morphine four hours before the ibogaine. Directory guides quote 12 to 24 hours after the last short-acting opioid, in mild to moderate withdrawal, and some clinics require a documented 48-hour opioid-free period verified by a urine screen at intake.

What the studies found

Brown and Alper, 2018 (American Journal of Drug and Alcohol Abuse): 30 patients who had failed other treatment, at two Mexican clinics, followed for 12 months, no control group. Withdrawal scores fell from 31 to 14 within about three days. The share reporting no opioid use in the previous 30 days was 50% at one month, 33% at three, 20% at six, 37% at nine and 23% at twelve months, counting everyone enrolled; only 12 of the 30 could still be reached at twelve months. The author's own listed limitations: results only from those who stayed in contact, little regulation of the clinics, treatment far from home, and most patients had no follow-up care.
Noller, Frampton and Yazar-Klosinski, 2018: 15 patients in New Zealand, where ibogaine was available on prescription, 71% of them on methadone; one participant died during treatment, a death the coroner tied to ibogaine and most probably a cardiac arrhythmia. Among those who could be followed, urine screens were negative in 6 of 8 at twelve months and 12 of 14 had reduced or stopped opioid use by self-report.
Mash and colleagues, 2018: a retrospective series of 191 patients (102 opioid, 89 cocaine) at a 12-bed inpatient facility in St. Kitts, 8 to 12 mg/kg with telemetry, patients with a slow heart rate or long QT excluded. Withdrawal scores fell from about 7 to about 0.85 at 36 hours; no serious adverse events or deaths; one-month follow-up was available for a minority. The lead author holds patents on noribogaine.
Malcolm, Polanco and Barsuglia, 2018: 50 patients in a week-long protocol; at 48 hours after dosing, 78% showed no objective withdrawal signs and 79% reported minimal craving. No control group.
Davis and colleagues, 2017: an anonymous online survey of 88 former patients of one Rosarito clinic. 80% said withdrawal was eliminated or drastically reduced; 30% said they never returned to opioids; 70% relapsed at some point, about half of them at lower use. Self-selected and self-reported.
Knuijver and colleagues, 2022: the only prospective hospital safety study, 14 methadone or buprenorphine patients at a Dutch university hospital, switched to morphine for eight days, then 10 mg/kg. Withdrawal scores went to a median of zero, but half the patients exceeded a QTc of 500 ms, half had bradycardia, and 3 of 14 restarted morphine within 24 hours. The authors concluded that routine use for opioid use disorder "cannot be justified" because of the QT effect.

The reviews say the same thing in the same words. Köck and colleagues (2022) found three placebo-controlled trials among 24 studies and "scarce" controlled evidence. Mosca and colleagues (2023) found only two double-blind studies and "a high risk of mortality", mostly cardiac and mostly outside clinics. A 2026 scoping review counted eight human efficacy studies from 1994 to 2018, all case series or observational, and "no randomized, placebo-controlled clinical trials" of efficacy. The one placebo-controlled randomised trial in this family tested noribogaine, the metabolite, in 27 methadone patients and found a non-significant trend in withdrawal ratings with dose-dependent QT prolongation.

What that adds up to: ibogaine reliably interrupts acute opioid withdrawal in the published series, often dramatically, in people who were monitored and medically screened. Whether it keeps people off opioids afterwards is not established; the cohorts that followed people for a year found most had used again, and the groups were small and self-selected. Nothing published compares it to buprenorphine, methadone, naltrexone or sedation-assisted detox head to head.

After you go home

Tolerance is reset. The guidelines tell every patient that an opioid dose that was normal before treatment can be fatal afterwards. Programs differ in what they offer: integration calls, boosters, microdoses, coaching. If you want a medication that blocks opioids afterwards, naltrexone is what the US sedation detox programs and ANR use; no ibogaine program on this site mentions it.

Sources

Not medical advice. Do not change a methadone or buprenorphine dose without the prescriber who manages it.